Ireland· IE-PA-EU/1/24/1808/001
Emblaveo 1.5 g/0.5 g powder for concentrate for solution for infusion
A aztreonam und beta-lactamase-inhibitor product containing avibactam sodium + aztreonam beta form, registered in Ireland by Pfizer Europe MA EEIG. The same ATC class is registered in 7 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Aztreonam und beta-lactamase-inhibitor is registered in 7 of 19 countries.
Countries holding a registration under ATC J01DF51 (aztreonam und beta-lactamase-inhibitor), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 4 of them publish a price we can compare per daily dose
Aztreonam und beta-lactamase-inhibitor · ATC J01DF51
7 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Ireland
- Netherlands
- Norwayprice
The record
At a glance
HPRA (Ireland)- Active substance
- Avibactam sodium + Aztreonam beta form
- Manufacturer
- Pfizer Europe MA EEIG
- Country
- Ireland (IE)
- ATC code
- J01DF51
- ATC class
- Aztreonam und Beta-Lactamase-Inhibitor
- Defined daily dose
- 6 g, P
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/24/1808/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Aztreonam und beta-lactamase-inhibitor in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesEMBLAVEOAbbVie Inc.
- SpainEMBLAVEO 1,5 G/0,5 G POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONPfizer Europe Ma Eeig
- FinlandEmblaveoPfizer Europe MA EEIG
- FranceEMBLAVEO 1,5 g/0,5 g, poudre pour solution à diluer pour perfusionPFIZER EUROPE MA EEIG (BELGIQUE)
- United KingdomEmblaveo 1.5g/0.5g powder for concentrate for solution for infusion vialsPfizer Ltd
- CzechiaEMBLAVEOPfizer Europe MA EEIG, Bruxelles
- NorwayEmblaveoPfizer Europe MA EEIG
- PolandEmblaveoPfizer Europe MA EEIG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Emblaveo
- Liechtenstein · Emblaveo
- Norway · Emblaveo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a70148ba-7bd6-40d1-be27-e9b9f3dd321a GET /v1/drugs/a70148ba-7bd6-40d1-be27-e9b9f3dd321a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Powder for concentrate for solution for infusion",
"routes": [
"Intravenous use"
],
"source": "hpra",
"atc_all": [
"J01DF51"
],
"strength": null,
"pa_number": "EU/1/24/1808/001",
"substances": [
"Avibactam sodium",
"Aztreonam beta form"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "22/04/2024",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about aztreonam und beta-lactamase-inhibitor.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.